NCT02455999View on ClinicalTrials.gov

Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2016

Conditions
Ocular PainDry Eye Syndrome
Interventions
DRUG

SYL1001

SYL1001 eye drops dose C administration for 10 consecutive days

DRUG

SYL1001

SYL1001 eye drops dose D administration for 10 consecutive days

DRUG

Placebo

Placebo eye drops administration for 10 consecutive days

Trial Locations (6)

10138

East Tallinn Central Hospital, Tallinn

13419

Eye Clinic Dr. Krista Turman, Tallinn

28034

Hospital Universitario Ramón y Cajal, Madrid

28040

Fundación Jiménez Díaz, Madrid

Hospital U. Clínico San Carlos, Madrid

31008

Clínica Universidad de Navarra, Pamplona

All Listed Sponsors
lead

Sylentis, S.A.

INDUSTRY

NCT02455999 - Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain | Biotech Hunter | Biotech Hunter